Literature DB >> 10402490

Modulation of biological phenotypes for tumor growth and metastasis by target-specific biological inhibitors in gastric cancer.

S Y Rha1, S H Noh, T S Kim, N C Yoo, J K Roh, J S Min, B S Kim.   

Abstract

For tumor progression, a cascade of linked sequential biological events is essential. We tried to test whether biological therapy can modulate specific biological phenotypes and increase the anti-tumor effect when combined with chemotherapy. Five human gastric cancer cell lines (YCC-1, YCC-2, YCC-3, YCC-7, AGS) were used in these studies. Pentosan polysulfate (PPS) as a heparin-binding growth factor inhibitor, Tranexamic acid as a plasmin inhibitor, Lovastatin as an adhesion inhibitor and Adriamycin as a chemotherapeutic agent were selected. The effects of each drug on colony formation and tumor cell proliferation were evaluated by soft agar assay and cell proliferation assay, respectively to test direct anti-tumor effect. The expression of uPA, PAI-1 was determined by ELISA, while MMPs activity was evaluated by zymography. PPS suppressed the colony-forming activity as much as Adriamycin did, but it showed only cytostatic effects in cell proliferation assay. Migration capacity using Boyden chamber assay was more closely correlated with adhesive capacity than uPA or MMP-2 expression. The motility inhibitory effect of Tranexamic acid was observed in the YCC-7 cell line, which expressed all the required biological phenotypes for migration. In AGS, with high cell motility and adhesiveness, the adhesion was inhibited by Lovastatin and most of the inhibitory effect was recovered by Mevalonate. When PPS was combined with Adriamycin on the Adriamycin-resistant, midkine (MK) gene expressing YCC-7 cell line, the growth inhibition rate increased up to 84%, while that for a single treatment of PPS or Adriamycin was 40% and 22%, respectively (p=0.001). When we combined Tranexamic acid and Adriamycin, we observed the synergistic effect in YCC-3 and YCC-7, while no combined effect was found in YCC-1. The combination of Lovastatin and Adriamycin did not show any combined effects in any of the cell lines. In conclusion, a synergistic anti-proliferative effect (chemo-sensitization) with combined chemo-biotherapy was found in cancer cells with specific biological target, MK. The anti-motility effect was the greatest when the gastric cancer cells expressed all the specific biological phenotypes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10402490     DOI: 10.3892/ijmm.4.2.203

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  4 in total

1.  Construction of a fusion protein expression vector MK-EGFP and its subcellular localization in different carcinoma cell lines.

Authors:  Li-Cheng Dai; Di-Yong Xu; Xing Yao; Li-Shan Min; Ning Zhao; Bo-Ying Xu; Zheng-Ping Xu; Yong-Liang Lu
Journal:  World J Gastroenterol       Date:  2006-12-21       Impact factor: 5.742

2.  Over-expressed and truncated midkines promote proliferation of BGC823 cells in vitro and tumor growth in vivo.

Authors:  Qing-Ling Wang; Hui Wang; Shu-Li Zhao; Ya-Hong Huang; Ya-Yi Hou
Journal:  World J Gastroenterol       Date:  2008-03-28       Impact factor: 5.742

3.  Decreased TOB1 expression and increased phosphorylation of nuclear TOB1 promotes gastric cancer.

Authors:  Rongwei Guan; Lei Peng; Dong Wang; Hongjie He; Dexu Wang; Rui Zhang; Hui Wang; Huiting Hao; Jian Zhang; He Song; Shuning Sui; Xiangning Meng; Xiaobo Cui; Jing Bai; Wenjing Sun; Songbin Fu; Jingcui Yu
Journal:  Oncotarget       Date:  2017-09-08

4.  Autophagy-mediated degradation of NOTCH1 intracellular domain controls the epithelial to mesenchymal transition and cancer metastasis.

Authors:  Sahib Zada; Jin Seok Hwang; Trang Huyen Lai; Trang Minh Pham; Mahmoud Ahmed; Omar Elashkar; Wanil Kim; Deok Ryong Kim
Journal:  Cell Biosci       Date:  2022-02-14       Impact factor: 7.133

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.